Clinical trials: Hemostatis
Dura Mater Nick Cut or Tear, Hemostatis
Hemopatch Performance Evaluation: A Prospective Observational Registry
To assess the clinical performance and safety of HEMOPATCH Sealing Hemostat in a post-marketing setting in cardiovascular, thoracic, urologic, neurological, and other general surgical procedures.
- Conditions
- Dura Mater Nick Cut or Tear, Hemostatis, Air Leakage, Body Fluid Leakage
- Trial name
- NCT03392662
- Testing
- Hemopatch
- Where
- 15 sites in Austria, Czechia and 3 more
- Volunteers
- 621 people
- Sponsor
- Baxter Healthcare Corporation